{"id":"W4313252357","doi":"10.1016/j.xkme.2022.100596","title":"Polycystic Kidney Disease Drug Development: A Conference Report","year":2022,"lang":"en","type":"article","venue":"Kidney Medicine","topic":"Genetic and Kidney Cyst Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; PKD Australia; European Medicines Agency; Universitätsklinikum Köln; Otsuka Pharmaceutical; Government of South Australia; Heinrich Hertz Stiftung; European Paediatric Neurology Society; University of Colorado; University of Kansas; University of Chicago; Tufts Medical Center; Manitoba Beekeepers' Association; Children's Hospital of Philadelphia; American Society of Nephrology; University of Toronto; Case Western Reserve University; U.S. Department of Health and Human Services; Yale University; PKD Foundation; Tufts University School of Medicine; Universitair Ziekenhuis Gent; Mayo Clinic","keywords":"Autosomal dominant polycystic kidney disease; Tolvaptan; Polycystic kidney disease; Medicine; PKD1; Drug development; Disease; Intensive care medicine; Kidney disease; Internal medicine; Lenvatinib; Bioinformatics; Drug; Pharmacology; Biology; Heart failure; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0158563,0.00324983,0.001253534,0.002363361,0.00206192,0.01078481,0.002897266,0.01203835,0.01971115],"category_scores_gemma":[0.01173132,0.0006908212,0.001847025,0.002277528,0.001131288,0.006135021,0.006668925,0.0118651,0.01200156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004332131,"about_ca_system_score_gemma":0.01150008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001966256,"about_ca_topic_score_gemma":0.004824089,"domain_scores_codex":[0.9900182,0.001571075,0.0005959526,0.0007431859,0.005625022,0.00144647],"domain_scores_gemma":[0.9861887,0.001793506,0.001015317,0.0003479655,0.005952673,0.00470183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009486559,0.0002518661,0.0002023191,0.0004846874,0.00002844421,0.000299598,0.00005167062,0.0003972464,0.0006198669,0.002519686,0.8955233,0.09952646],"study_design_scores_gemma":[0.00004995677,0.0002034792,0.0003782997,0.0005653843,0.00002304069,0.0002365635,0.00006853026,0.0002821622,0.0005462997,0.001641313,0.9959786,0.00002642072],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.003775194,0.2305363,0.006813122,0.3283769,0.3385107,0.001332113,0.001551849,0.0006332361,0.08847068],"genre_scores_gemma":[0.02817213,0.2925769,0.01116489,0.1469138,0.2437651,0.002177329,0.005176767,0.0006334112,0.2694196],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01971115,"threshold_uncertainty_score":0.08385718,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01219201171451289,"score_gpt":0.250738858133489,"score_spread":0.2385468464189761,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}